(Phys.org) —There's hope for patients with myotonic dystrophy. A new small molecule developed by researchers at the University of Illinois has been shown to break up the protein-RNA clusters that cause the disease in living human cells, an important first step toward developing a pharmaceutical treatment for the as-yet untreatable disease.
Steven C. Zimmerman, the Roger Adams Professor of Chemistry at the U. of I., led the group in developing and demonstrating the compound. The National Institutes of Health supported the work published in the journal ACS Chemical Biology.
Myotonic dystrophy type 1 is the most common form of muscular dystrophy in adults, affecting one in 8,000 people in North America. It causes progressive weakness as the muscles deteriorate over time. There is no treatment available for the disease; though a few measures can help ease some symptoms, nothing can halt their inevitable progression.
"This is a disease that currently doesn't have any treatment, so we have a huge interest in finding therapeutic agents," said graduate student Amin Haghighat Jahromi, the first author of the paper.
Myotonic dystrophy type 1, called DM1 for short, is caused by a mutation to one gene. In a healthy person, one small segment of the gene – a DNA sequence of CTG – is repeated a few times. In someone with DM1, the sequence is repeated more than 50 times, even up to thousands of repeats. The sequence is transcribed into RNA over and over, like a skipping record stuck in a loop. The repetitive RNA binds to the protein MBNL1, which is essential for regulating protein balance in cells. The RNA traps the MBNL1 protein in aggregates within the cell's nucleus.
In myotonic dystrophy, a mutation causes RNA to bind to an important protein in the cell nucleus. A new molecule developed at the University of Illinois causes the RNA to “let go” of the protein, breaking up the nuclear clusters. Credit: L. Brian Stauffer"The RNA is functioning in an abnormal way, and unfortunately, it's toxic," Zimmerman said. "MNBL regulates a process called alternative splicing that controls how much of different proteins are made. Affected cells make the proteins, just not at the right levels, so all the levels are imbalanced. There are more than 100 proteins that are affected."
The Illinois group developed a small molecule that could infiltrate the nucleus and bind to the RNA, forcing it to let go of MBNL1 so the protein can do its job. The molecule is small and water-soluble so it can cross the membrane into the cell, which has been a challenge for researchers attempting to use methods with larger molecules. It specifically targets only the repeating RNA sequence so as not to interfere with other cellular functions.
The researchers administered the molecule to live cells that have the disease features of DM1. Using advanced microscopy methods, they were able to watch the cells over time to see how they responded to the molecule. In only a few hours, they saw the clusters within the nucleus break up and were able to measure that the MBNL1 protein had increased its regulatory activity.
"This is the first study that gives direct evidence for the function of the compound," Jahromi said. "We track how the cell is changing upon treatment with the compound and see the effect directly."
Next, the researchers plan to begin collaborating with other groups to test their molecule in fruit flies and mice. Although the molecule will need many rounds of testing for toxicity, efficacy, metabolism and possible side effects before human trials can begin, finding a molecule that works in living cells is an important first step toward making a drug that could treat myotonic dystrophy.
"We're close to developing drug candidates that can be tested in animals. And if it works in animals, then we move hopefully into clinical trials with humans," Zimmerman said. "It's heartbreaking, at one level, to say we're years away from something that's going to be in the clinic. On the other hand, we now have targets. We now know how to go after this disease. It gives patients and their families a bit of hope."
A proof version of the paper, "A Novel CUGexp·MBNL1 Inhibitor With Therapeutic Potential for Myotonic Dystrophy Type 1," is available online.
Explore further: Scientists create new approach to destroy disease-associated RNAs in cells
9 hours ago Hi guys, I'm having a bit of difficulty understanding Pourboix diagrams. The biggest problem at the moment is that I don't clearly understand what... 10 hours ago Hi to all, I want to know the temperature after combustion of methane with air. How will i calculate it? Kindly inform me. Regards,... Apr 28, 2013 I am familiar with the equation ?G=?G°+RT ln(Q).But I can't derive it.We have to use the equation to derive nernst equation. So please help. Apr 28, 2013 Hi, can someone please explain to me how I can identify which is the oxidation half and which is the reduction half of a redox reaction. I have read... Apr 27, 2013 I have been urinating into a plastic bottle lately (I will not elaborate why), and have been finding the bottle to hold a vacuum the following... Apr 27, 2013 Can someone outline a comprehensive way to figure out and write all the different isomers of square planar and octahedral single-centre coordination... Jan 24, 2010 Research on the genetic defect that causes myotonic muscular dystrophy has revealed that the mutation disrupts an array of metabolic pathways in muscle cells through its effects on two key proteins. A study published in Nature St ...
Sep 07, 2009 Researchers at the University of Illinois have designed a small molecule that blocks an aberrant pathway associated with myotonic dystrophy type 1, the most common form of muscular dystrophy.
Feb 22, 2012 While RNA is an appealing drug target, small molecules that can actually affect its function have rarely been found. But now scientists from the Florida campus of The Scripps Research Institute have for the first time designed ...
Nov 19, 2008 Scientists have identified a promising set of new compounds in the fight against muscular dystrophy. Using a drug-discovery technique in which molecules compete against each other for access to the target – the strand of ...
5 hours ago (Phys.org) —While the natural world is replete with compounds that form the basis of many disease-fighting pharmaceuticals, it is also the case that humans and other mammals produce their own host-defense ...
Apr 29, 2013 (Phys.org) —A combined team of researchers from the U.S. and Slovenia has succeeded in creating "origami" type proteins that assemble themselves into three dimensional shapes. As a proof of concept, the ...
Apr 25, 2013 (Phys.org) —Changes in the bases that make up DNA act as markers, telling a cell which genes it should read and which it shouldn't. In the journal Angewandte Chemie, a British team has now introduced a new ...
Apr 24, 2013 Life on Earth may have originated not in warm tropical seas, but with weird tubes of ice—sometimes called "sea stalactites"—that grow downward into cold seawater near the Earth's poles, scientists are ...
(Phys.org) —While the natural world is replete with compounds that form the basis of many disease-fighting pharmaceuticals, it is also the case that humans and other mammals produce their own host-defense ...
From methanol to formaldehyde - this reaction is the starting point for the synthesis of many everyday plastics. Using catalysts made of gold particles, formaldehyde could be produced without the environmentally ...
Researchers have found that reusing the by-products of fruit and cereal processing could help promote the sustainability of the food industry, as long as its overall environmental fingerprint is clearly evaluated.
(Phys.org) —A combined team of researchers from the U.S. and Slovenia has succeeded in creating "origami" type proteins that assemble themselves into three dimensional shapes. As a proof of concept, the ...
(Phys.org) —Scientists have discovered further evidence for the existence of new molecules in the atmosphere that have the potential to off-set global warming by reacting with airborne pollutants.
Although eleventh-century Vikings did not have magnetic compasses at their disposal, it is thought that they could determine their orientation at sea using sun-compasses. Sun-compasses use the position of ...
The atoms that make up ordinary matter fall down, so do antimatter atoms fall up? Do they experience gravity the same way as ordinary atoms, or is there such a thing as antigravity?
Pick up your smartphone. How are financial markets faring? Check Dow Jones or the S&P 500. Average temperature in the United State last July 4th? Steer your iPad over to the National Weather Service. OK, ...
A quantum computer is controlled by the laws of quantum physics; it promises to perform complicated calculations, or search large amounts of data, at a speed that exceeds by far those that today's fastest supercomputers are ...
(Phys.org) —As planets age they become darker and cooler. Saturn however is much brighter than expected for a planet of its age - a question that has puzzled scientists since the late sixties. New research ...
© Phys.org™ 2003-2013var _comscore = _comscore || [];var csDocDomain = document.location.href; _comscore.push({ c1: "2", c2: "6035753", c3: "6035753", c4: csDocDomain }); (function() { var s = document.createElement("script"), el = document.getElementsByTagName("script")[0]; s.async = true; s.src = (document.location.protocol == "https:" ? "https://sb" : "http://b") + ".scorecardresearch.com/beacon.js"; el.parentNode.insertBefore(s, el);})();
No comments:
Post a Comment